Lipocine (NASDAQ:LPCN) Shares Pass Below 200-Day Moving Average – What’s Next?

Shares of Lipocine Inc. (NASDAQ:LPCN) crossed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $3.90 and traded as low as $2.17. Lipocine shares last traded at $2.23, with a volume of 41,499 shares trading hands.

Wall Street Analyst Weigh In

Several equities analysts recently commented on LPCN shares. Wall Street Zen raised Lipocine from a “sell” rating to a “hold” rating in a research report on Saturday, July 18th. Weiss Ratings upgraded shares of Lipocine from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, August 19th. One research analyst has rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Reduce” and an average target price of $15.00.

Lipocine Price Performance

The stock has a market cap of $17.88 million, a PE ratio of -1.21 and a beta of 0.46. The business has a fifty day moving average of $2.24 and a 200 day moving average of $3.89.

Lipocine (NASDAQ:LPCN) last posted its quarterly earnings data on Tuesday, August 4th. The specialty pharmaceutical company reported ($0.32) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.40) by $0.08. The company had revenue of $0.19 million for the quarter, compared to the consensus estimate of $0.21 million. Lipocine had a negative return on equity of 64.75% and a negative net margin of 755.39%. On average, equities research analysts expect that Lipocine Inc. will post -1.91 EPS for the current year.

Institutional Investors Weigh In On Lipocine

Hedge funds and other institutional investors have recently modified their holdings of the stock. Citadel Advisors LLC acquired a new stake in shares of Lipocine in the 3rd quarter valued at about $41,000. Geode Capital Management LLC increased its holdings in Lipocine by 2.2% in the fourth quarter. Geode Capital Management LLC now owns 62,450 shares of the specialty pharmaceutical company’s stock valued at $502,000 after buying an additional 1,374 shares during the last quarter. Renaissance Technologies LLC raised its stake in Lipocine by 3.6% during the fourth quarter. Renaissance Technologies LLC now owns 37,397 shares of the specialty pharmaceutical company’s stock valued at $300,000 after buying an additional 1,300 shares in the last quarter. Jane Street Group LLC acquired a new stake in Lipocine during the fourth quarter valued at approximately $85,000. Finally, Persistent Asset Partners Ltd bought a new position in Lipocine during the 4th quarter worth approximately $567,000. Institutional investors own 9.11% of the company’s stock.

Lipocine Company Profile

Lipocine Inc is a clinical-stage pharmaceutical company focused on the development and commercialization of oral drug delivery technologies. The company’s core expertise lies in lipid-based formulations designed to improve the bioavailability of therapeutics that traditionally require injectable administration. By leveraging proprietary technologies, Lipocine aims to offer patient-friendly alternatives with the potential for more consistent pharmacokinetic profiles and improved compliance.

The company’s lead product, TLANDO (LPCN 1021), is an oral testosterone replacement therapy approved by the U.S.